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Maternal tolerance to the fetus is fundamental for suc-
cessful reproduction. Derangement of this process may
play a role in the pathogenesis of obstetrical diseases,
such as preeclampsia (PE), miscarriages, and fetal
growth restriction. The action of regulatory T cells (Tregs)
has been proposed among the immunosuppressive
mechanisms that maintain maternal-fetal immune toler-
ance.1 Tregs are a subset of CD4 T cells specialized in
the suppression of the immune response against self-
antigens. Tregs are characterized by the expression of
the transcription factor, Foxp3, which is required for their
differentiation and function.2 Foxp3 Tregs can be gen-
erated in the thymus, referred to as naturally occurring
Tregs (nTregs), or they can be generated in the periphery
as a result of the conversion of naïve CD4 T cells into
Foxp3 Tregs, referred to as induced Tregs (iTregs) or
peripheral Tregs.3 In this issue of The American Journal of
Pathology, Hsu et al4 report an enrichment in iTregs in
normal pregnancy but not in PE and argue that this defect
in iTregs may be central to the pathogenesis of PE.
PE is characterized by hypertension and proteinuria
after 20 weeks of gestation. It complicates 3% to 8% of all
pregnancies and is a leading cause of maternal and
perinatal morbidity and mortality.5 Epidemiological data
suggest that immunological mechanisms may play a role
in the pathogenesis of the disease.6 Decreased exposure
to sperm, such as in the case of intracytoplasmic sperm
injection for azoospermia, short duration of sexual cohab-
itation with the father, barrier contraception, and nonpart-
ner donor insemination have been associated with an
increased risk of PE.7–10 The risk of PE is higher in first
pregnancies, and multiparous women pregnant with a
new partner have a risk similar to nulliparous women. It is
1900still not clear if this effect is due to the change in paternity
per se or to the greater risk associated with an increased
interpregnancy interval.11,12 During normal pregnancy,
Tregs are present at the maternal-fetal interface as well
as peripheral blood. Most studies,13–15 but not all,16 have
previously reported that there is decreased numbers of
Tregs in peripheral blood in women with PE. Moreover,
decidual Tregs have also been reported to be lower in PE
when compared with normal pregnancies.17
Hsu et al4 analyzed human decidual and peripheral
blood Treg populations in healthy and preeclamptic
pregnancies. CD4 Helios Foxp3 Tregs, but not CD4
Helios Foxp3 Tregs, were overrepresented in the pe-
ripheral blood of healthy pregnant individuals when com-
pared with nonpregnant or preeclamptic patients. Al-
though both healthy and preeclamptic pregnancies
presented a higher percentage of Foxp3 Tregs in the
decidua compared with the peripheral blood, decidual
Foxp3 Tregs were enriched in Helios cells in normal
pregnancies but not in PE. These results suggest an
induction of Helios Foxp3 Tregs during pregnancy,
both in blood and locally in the decidua or in decidual
draining lymph nodes that is impaired in PE.
The association of Helios Foxp3 Treg deficiency
with PE is particularly interesting in the context of re-
cent findings in mice. A Foxp3 locus noncoding DNA
sequence, CNS1, that is necessary for the generation
of iTregs, but not nTregs,18 was required for the gen-
eration of iTreg cells specific for a paternal model
alloantigen during pregnancy. These iTregs accumu-
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nodes. More important, CNS1-deficient females pre-
sented increased embryo resorption rates and defec-
tive spiral artery remodeling, a feature also observed in
human preeclamptic deciduas, in allogeneic, but not in
syngeneic, matings.19
Interestingly, to evaluate the cause of this iTreg deficit
in PE, the authors studied DC-SIGN antigen-presenting
cells (APCs). Most Foxp3 cells were associated with
DC-SIGN APCs in decidua preparations. The number of
Foxp3 and DC-SIGN cells was highly correlated in
normal pregnancy samples but not in samples from pre-
eclamptic patients, suggesting an impairment in the DC-
SIGN APC/Treg interaction in PE. The authors demon-
strate that decidual CD14 DC-SIGN APCs from
preeclamptic pregnancies induced significantly fewer
Foxp3 cells, most of which were Helios, than CD14
DC-SIGN APCs from healthy pregnancies in alloprolif-
eration assays. Co-culture of CD4 CD25 T cells with
decidual CD14 DC-SIGN APCs from healthy pregnant
women resulted in more Foxp3 cells, which were largely
Helios, among the proliferating cells than when the co-
cultures were performed with CD14 DC-SIGN decidual
APCs. The percentage of Foxp3 T cells (non-Tregs) in-
versely correlated with the percentage of Foxp3 cells gen-
erated, indicating that the induced cells were functional
Tregs. No differences were observed in the percentage of
Foxp3 cells induced between CD14 DC-SIGN and
CD14 DC-SIGN APCs from preeclamptic patients, indi-
cating that the capacity of Foxp3 Treg induction by
CD14 DC-SIGN APCs is affected in PE.
This work has some limitations and implications for
future studies. The use of Helios to discriminate Treg
subtypes is not optimal. Helios is a member of the Ikaros
family of transcription factors and was proposed as a
marker of nTregs. However, this has later been chal-
lenged because Helios expression has also been shown
in both in vitro– and in vivo–induced murine Foxp3
iTregs,20–22 and Helios has been proposed as a marker
of T-cell activation in both mice and humans.22 In this
context, CD4 Helios Foxp3 cells could still represent
iTregs, albeit on further confirmation. The facts that de-
cidual DC-SIGN APCs can induce Helios Foxp3 cells
in in vitro assays and that decidual Tregs are associated
with decidual DC-SIGN APCs in tissue support the idea
that decidual Helios Foxp3 Tregs may, in fact, be
iTregs. More recently, neuropilin 1 has emerged as a
novel marker that differentiates nTregs and iTregs in
mice.23,24 If neuropilin 1 can also distinguish nTregs and
iTregs in humans, it would be interesting to confirm if
decidual Helios Foxp3 Tregs and Tregs induced by
decidual DC-SIGN APCs present an iTreg neuropilin 1
expression pattern.
Helios has also been proposed as a marker of T-cell
activation and proliferation, with regressed expression
under resting conditions.21,22 In this framework, Helios
Tregs in the periphery could reflect the presence of
iTregs or, as Gottschalk et al21 speculate, could also
represent a subset of iTregs or nTregs that differ in their
stimulation history in either temporal proximity to antigen
stimulation or the type of APCs to which they have beenexposed. Therefore, it would be important to understand
the phenotypical and functional difference between CD4
Helios Foxp3 and CD4 Helios Foxp3 Tregs and their
precise role in pregnancy.
In addition, it still needs to be determined if this deficit
in iTregs is the cause or the consequence of PE, because
there is no data available from subjects early in preg-
nancy, before the onset of clinical disease. Also, whether
the iTreg deficit is noted in other placentation disorders,
such as recurrent miscarriage or isolated intrauterine fe-
tal growth restriction, remains unknown. It would be im-
portant to evaluate whether soluble endoglin, a circulat-
ing transforming growth factor- signaling inhibitor that
has been linked with the pathogenesis of PE,25 may be
responsible for this iTreg deficit in PE. Furthermore, it
would be interesting to evaluate whether the iTreg deficit
in PE leads to defective spiral artery remodeling by alter-
ing decidual natural killer cell functions.
In summary, the novel findings by Hsu et al4 propose
an impaired induction of iTregs in PE, possibly through
impaired function of decidual APCs. The mechanistic
defects behind these findings and their functional signif-
icance raise multiple exciting questions regarding the
role of immune mechanisms in PE and related disorders.
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